May 22, 2023 / 08:30PM GMT
Operator
Good afternoon, and thank you for attending today's Blueprint Medicines Conference Call. My name is Daniel, and I will be the moderator for today's call. (Operator Instructions) It is now my pleasure to pass the conference over to our host, Jenna Cohen with Blueprint. Jenna, the floor is yours.
Jenna Cohen - Blueprint Medicines Corporation - Senior Director & Head of IR
Thank you, Daniel, and good afternoon, everyone. It is an honor and a pleasure to welcome you to Blueprint Medicines conference call to discuss the U.S. FDA approval of AYVAKIT for indolent systemic mastocytosis. This afternoon, we issued a press release outlining this historic milestone for Blueprint Medicines and the SM community. You can access the press release as well as the slides that we'll be reviewing today by going to the Investors section of our website at www.blueprintmedicines.com.
Joining us today are Kate Haviland, Chief Executive Officer; Becker Hewes, Chief Medical Officer; and Philina Lee,
Blueprint Medicines Corp To Discuss The FDA Approval of AYVAKIT in ISM Call Transcript
May 23, 2023
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers